Image 3_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Results<p>In total, 15 types of decreased autoantibodies were identified, and 6 of them were constructed into a predictive model for early lung cancer, reaching a sensitivity of 76.19% and a specificity of 55.74%. …"

Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Results<p>In total, 15 types of decreased autoantibodies were identified, and 6 of them were constructed into a predictive model for early lung cancer, reaching a sensitivity of 76.19% and a specificity of 55.74%. …"

Image 2_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Results<p>In total, 15 types of decreased autoantibodies were identified, and 6 of them were constructed into a predictive model for early lung cancer, reaching a sensitivity of 76.19% and a specificity of 55.74%. …"

Image 4_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Results<p>In total, 15 types of decreased autoantibodies were identified, and 6 of them were constructed into a predictive model for early lung cancer, reaching a sensitivity of 76.19% and a specificity of 55.74%. …"

Image 5_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Results<p>In total, 15 types of decreased autoantibodies were identified, and 6 of them were constructed into a predictive model for early lung cancer, reaching a sensitivity of 76.19% and a specificity of 55.74%. …"

Image 8_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Results<p>In total, 15 types of decreased autoantibodies were identified, and 6 of them were constructed into a predictive model for early lung cancer, reaching a sensitivity of 76.19% and a specificity of 55.74%. …"

Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for access question between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues and c... حسب David Henderson (4612354)

Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for overall satisfaction between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues... حسب David Henderson (4612354)

Increasing fractions of mobilized and static taxa in the microbial streamwater community, with a corresponding decrease in the fraction of diluted microbial taxa, detail the shift... حسب Dawn R. URycki (9659702)

Supplementary Material for: Allopurinol Use is Associated With Decreased Incidence of Hepatic Decompensation and Overall Mortality Among Individuals With Cirrhosis: a Propensity-ma... حسب figshare admin karger (2628495)

"…Conclusion: In a propensity-score matched analysis of a large national database, individuals with cirrhosis and allopurinol use had significantly lower risk of hepatic decompensation and overall mortality. …"

Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage. حسب Verónica M. Negrón-Pérez (20691412)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)